Ringwood, Australia – October 1, 2025 – Trajan Scientific and Medical (Trajan) today announced a collaboration with University of Calgary and the Schriemer Laboratory to accelerate innovation in hydrogen-deuterium exchange mass spectrometry (HDX-MS) and advance next-generation structural biology workflows.
The collaboration brings together the Schriemer Laboratory’s expertise in structural biology and analytical chemistry with Trajan’s capabilities in protein science, workflow-optimized automation, and analytical software platforms.
A central focus of the partnership is the continued development and refinement of integrated HDX-MS workflows leveraging Trajan’s CHRONECT automation ecosystem and CHRONECT studio software solutions.
This partnership goes well beyond a traditional vendor-laboratory relationship. The two organizations operate as an integrated team, creating a continuous, two-way exchange of expertise.
Working side by side, researchers and Trajan scientists co-develop, test, and validate new workflows and technologies across software, instrumentation, and consumables – all within a real-world end-user environment.
The collaboration spans practical application development, workflow optimization, and training to accelerate the adoption of emerging structural biology approaches. By combining academic research insight with applied workflow development, the partnership aims to reduce manual variability, improve reproducibility, and accelerate time-to-insight in protein structure analysis.
As part of the collaboration, Trajan is providing dedicated funding to support graduate students and laboratory personnel within the Schriemer Laboratory. This investment is intended to expand CHRONECT Studio development activities and support the creation of next-generation technologies in structural biology and mass spectrometry.
Beyond Trajan’s investment, the Schriemer Laboratory will continue its core mission of advancing fundamental scientific research while also contributing to the development of innovative technologies that aim to transform structural biology into a systems-wide discipline.
The collaboration is designed to bridge applied workflow development with discovery-driven science, enabling new approaches to understanding protein dynamics at scale. “This collaboration reflects Trajan’s commitment to working directly with leading academic researchers to advance practical innovation in HDX-MS,” said Kyle Bachus, VP of Pharma Solutions at Trajan. “This isn't a typical supplier arrangement, it's a true partnership. By embedding our teams in each other's environments, we're able to develop and refine technologies in the place where they'll ultimately be deployed to have an impact. At Trajan, our goal is simple – help the industry develop better drugs, faster – and that is exactly the impact this partnership is built to deliver.”
